STOCK TITAN

Standard BioTools holders approve Treeline merger plans

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Standard BioTools Inc. (LAB) stockholders approved all proposals related to the planned Treeline merger and Mass Cytometry business sale. The merger is expected to close in the fourth quarter of 2026, subject to remaining customary closing conditions; the sale to Element Biosystems, LLC is expected to close substantially concurrently. At the Special Meeting, 281,744,412 votes were present or represented, about 71.38% of voting power.

The approved charter amendment provides for a 1-for-20 to 1-for-40 reverse stock split, with the final ratio to be mutually agreed by Standard BioTools and Treeline, and changes the company’s name to Treeline Biosciences, Inc. Stockholders also approved post-closing equity incentive and employee stock purchase plans, which are contingent on the merger closing and take effect at the merger’s effective time. There were 394,711,296 common shares issued and outstanding and entitled to vote as of October 16, 2026.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Reverse stock split ratio 1-for-20 to 1-for-40 Approved range; final ratio to be mutually agreed by Standard BioTools and Treeline.
Common shares issued and outstanding 394,711,296 shares As of October 16, 2026; entitled to vote at the Special Meeting.
Votes present or represented 281,744,412 votes Special Meeting; constituted a quorum.
Voting power represented approximately 71.38% At the Special Meeting.
Votes for share issuance proposal 274,099,041 votes Special Meeting vote.
Votes for charter amendment proposal 275,584,914 votes Special Meeting vote.
Votes for Element Mass Cytometry Divestiture Proposal 276,299,544 votes Special Meeting vote.
Votes for Post-Closing Equity Incentive Plan Proposal 207,381,782 votes Special Meeting vote.
reverse stock split financial
"effect a reverse stock split of the Company’s issued and outstanding Common Stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
quorum regulatory
"constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
broker non-votes regulatory
"There were no broker non-votes with respect to any of the proposals."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
customary closing conditions technical
"subject to the satisfaction of remaining customary closing conditions"
"Customary closing conditions" are standard rules or checks that must be met before a business deal can be finalized, like making sure all paperwork is in order or that certain approvals are obtained. They matter because they help protect both parties, ensuring everything is in place and reducing the risk of surprises or problems after the deal is closed.
Employee Stock Purchase Plan financial
"Post-Closing Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Nasdaq Listing Rules regulatory
"in accordance with Nasdaq Listing Rules 5635(a) and 5635(b)"
Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is LAB’s merger with Treeline expected to close?

The merger is expected to close in the fourth quarter of 2026, subject to satisfaction of remaining customary closing conditions. The Mass Cytometry business sale to Element Biosystems, LLC is expected to close substantially concurrently with the merger.

What did LAB stockholders approve?

Stockholders approved all proposals related to the Treeline merger and Mass Cytometry sale, including the share issuance, charter amendment, post-closing equity incentive and employee stock purchase plans, advisory compensation, divestiture, and adjournment proposals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


 
FORM 8-K


 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (date of earliest event reported): November 19, 2026


 
Standard BioTools Inc.

(Exact name of registrant as specified in its charter)
 


Delaware
001-34180
77-0513190
(State or other jurisdiction of  incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)

50 Milk Street, 10th Floor
Boston, Massachusetts 02109
(Address of principal executive offices and zip code)
(650) 266-6000
(Registrant's telephone number, including area code)
 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☒
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol
 
Name of each exchange on which registered
Common stock, $0.001 par value per share
 
LAB
 
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As disclosed in Item 5.07 of this Current Report on Form 8-K, at the Special Meeting (as defined below), the stockholders of Standard BioTools Inc. (the “Company”) voted to approve the Post-Closing Equity Incentive Plan and the Post-Closing ESPP, each as defined in the Company’s definitive proxy statement/prospectus (the “Proxy Statement/Prospectus”), filed with the Securities and Exchange Commission (the “SEC”) on October 21, 2026 pursuant to Rule 424(b)(3) and forming part of the Company’s registration statement on Form S-4 (File No. 333-297560), which was declared effective by the SEC on October 21, 2026. The Post-Closing Equity Incentive Plan and the Post-Closing ESPP will become effective at the effective time of the Merger (as defined in the Proxy Statement/Prospectus) and are each contingent on the closing of the Merger.

The material features of the Post-Closing Equity Incentive Plan and the Post-Closing ESPP are set forth in the Proxy Statement/Prospectus. Those summaries and the foregoing descriptions are qualified in their entirety by reference to the complete text of the Post-Closing Equity Incentive Plan and the Post-Closing ESPP, copies of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and incorporated in this Item 5.02 by reference.

Item 5.07.
Submission of Matters to a Vote of Security Holders.

On November 19, 2026, the Company held a virtual special meeting of stockholders (the “Special Meeting”) to vote on the proposals identified in the Proxy Statement/Prospectus.

At the close of business on October 16, 2026, the record date for the Special Meeting, there were 394,711,296 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued and outstanding and entitled to vote at the Special Meeting. A total of 281,744,412 votes, or approximately 71.38% of the total voting power of the shares of the Company’s capital stock issued and outstanding and entitled to vote at the Special Meeting, were present virtually or represented by proxy at the Special Meeting, constituting a quorum. The following proposals are described in detail in the Proxy Statement/Prospectus. The final voting results for each of the matters submitted to a vote of the Company’s stockholders at the Special Meeting are set forth below:

1. Share Issuance Proposal. The proposal to approve the issuance of shares of Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rules 5635(a) and 5635(b) was approved by the following votes:

Votes For
 
Votes Against
 
Abstentions
         
274,099,041
 
7,571,806
 
73,565
 
2. Charter Amendment Proposal. The proposal to approve an amendment to the Company’s Eighth Amended and Restated Certificate of Incorporation, as amended, to (i) effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio in the range from 1-for-20 to 1-for-40, inclusive, with the final ratio to be mutually agreed to by the Company and Treeline Biosciences, Inc., and (ii) change the name of the Company to “Treeline Biosciences, Inc.” was approved by the following votes:


Votes For
 
Votes Against
 
Abstentions
         
275,584,914
 
6,123,396
 
36,102

3. Post-Closing Equity Incentive Plan Proposal. The proposal to approve the Post-Closing Equity Incentive Plan, which will become effective at the effective time of the Merger and is contingent on the closing of the Merger, was approved by the following votes:

Votes For
 
Votes Against
 
Abstentions
         
207,381,782
 
57,483,106
 
16,879,524

4. Post-Closing ESPP Proposal. The proposal to approve the Post-Closing Employee Stock Purchase Plan (as defined in the Proxy Statement/Prospectus), which will become effective at the effective time of the Merger and is contingent on the closing of the Merger, was approved by the following votes:

Votes For
 
Votes Against
 
Abstentions
         
224,903,287
 
39,976,090
 
16,865,035
 
5. Advisory Compensation Proposal. The proposal to approve, on a nonbinding, advisory basis, the Transaction-Related Compensation (as defined in the Proxy Statement/Prospectus) was approved by the following votes:
Votes For
 
Votes Against
 
Abstentions
         
248,805,322
 
15,966,136
 
16,972,954

6. Element Mass Cytometry Divestiture Proposal. The proposal to approve the Element Mass Cytometry Divestiture (as defined in the Proxy Statement/Prospectus), which may be considered a sale of substantially all of the assets of the Company under Section 271 of the Delaware General Corporation Law, was approved by the following votes:

Votes For
 
Votes Against
 
Abstentions
         
276,299,544
 
5,336,020
 
108,848

7.  Adjournment Proposal. The proposal to approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Share Issuance Proposal and/or the Charter Amendment Proposal if there are insufficient votes at the time of such adjournment to approve such proposals or to ensure that any supplement or amendment to the Proxy Statement/Prospectus is timely provided to the Company’s stockholders was approved by the following votes:

Votes For
 
Votes Against
 
Abstentions
         
255,788,813
 
9,049,389
 
16,906,210

There were no broker non-votes with respect to any of the proposals.


Item 7.01.
Regulation FD Disclosure.

On November 19, 2026, the Company issued a press release announcing that its stockholders voted to approve all proposals at the Special Meeting. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference.

The information set forth in this Item 7.01 and in the attached Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01.
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit No.
 
Description
10.1+
 
Post-Closing Equity Incentive Plan.
10.2+
 
Post-Closing ESPP.
99.1
 
Press Release, dated November 19, 2026.
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document).

+ Indicates management contract or compensatory plan or arrangement.


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:
November 19, 2026
STANDARD BIOTOOLS INC.
 

 
 
 

By:
/s/ Alex Kim
 

Name:
Alex Kim
 

Title:
Chief Financial Officer
 



Exhibit 99.1

Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and
Sale of Mass Cytometry Business

BOSTON, Mass., Nov. 19, 2026 – Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced that, at its Special Meeting of Stockholders held earlier today, stockholders approved all proposals related to the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”) and the sale of its Mass Cytometry business to Element Biosystems, LLC, an acquisition vehicle formed by GMT Venture Partners, LLC.

“We are pleased with the outcome of today’s vote and thank our stockholders for their support of these transactions,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “These approvals represent an important step toward completing our planned merger with Treeline and positioning our Mass Cytometry business for continued success under new ownership. We look forward to completing both transactions.”

The merger with Treeline is expected to close in the fourth quarter of 2026, subject to the satisfaction of remaining customary closing conditions. The sale of the Mass Cytometry business is expected to close substantially concurrently with the Treeline merger.

About Standard BioTools Inc.
Standard BioTools Inc. (NASDAQ: LAB) is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn and YouTube™.

Forward-Looking Statements
 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of the merger and the sale of the Mass Cytometry business. The words “will,” “toward,” “look forward,” “planned,” “position,” “expected,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions.
 

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (i) risks associated with the possible failure to satisfy the conditions to the closing or consummation of the merger and the sale of the Mass Cytometry business; (ii) risks associated with the uncertainty as to the timing of the consummation of the merger and the sale of the Mass Cytometry business and the ability of each of Standard BioTools and Treeline to consummate the transactions contemplated by the merger agreement; (iii) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger and the sale of the Mass Cytometry business prior to the closing or consummation of each; (iv) risks associated with the possible failure to realize certain anticipated benefits of the merger and the sale of the Mass Cytometry business, including with respect to future financial and operating results; (v) the effect of the completion of the merger and the sale of the Mass Cytometry business on the combined company’s business relationships, operating results and business generally; and (vi) the risk that the parties may assume unexpected liabilities and expenses as a result of the merger and the sale of the Mass Cytometry business. For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2026, Standard BioTools’ subsequent Quarterly Reports on Form 10-Q, Standard BioTools’ Form S-4 Registration Statement relating to the merger with Treeline and Standard BioTools’ other filings with the SEC. Should any of these risks or uncertainties materialize, actual results could differ materially from expectations. These forward-looking statements speak only as of the date hereof. Standard BioTools does not assume any obligation to, and does not currently intend to, update any such forward-looking statements except as may be required by law.
 
IR:
ir@standardbio.com

Media:
Dan Moore / Nick Lamplough / David Feldman
Collected Strategies
LAB-CS@collectedstrategies.com



Filing Exhibits & Attachments

6 documents

Keep reading